Floatz logo

Carboplatin

Lymphatic System Disorder

M.D. Anderson Cancer CenterSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Lymphatic System Disorder cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
UNC Lineberger Comprehensive Cancer Center
Phase 2B
Bendamustine
UNC Lineberger Comprehensive Cancer Center
Phase 2B
Zilovertamab
Oncternal Therapeutics, Inc
Phase 3B
Ibrutinib
Oncternal Therapeutics, Inc
Phase 3B
Brentuximab Vedotin
UNC Lineberger Comprehensive Cancer Center
Phase 2B

View all 20 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →